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Abstract
Background: Recent international guidelines recommend intra-articular corticosteroid injections for patients with
hip osteoarthritis who have moderate to severe pain and do not respond satisfactorily to oral analgesic/anti-
inflammatory agents. Of the five available randomized controlled trials, four showed positive effects with respect to
pain reduction. However, intra-articular injection in the hip is complex because the joint is adjacent to important
neurovascular structures and cannot be palpated. Therefore fluoroscopic or ultrasound guidance is needed.
The systemic effect of corticosteroids has been studied in patients with impingement shoulder pain. Gluteal
corticosteroid injection was almost as effective as ultrasound-guided subacromial corticosteroid injection. Such a
clinically relevant effect of a systemic corticosteroid injection offers a less complex alternative for treatment of
patients with hip osteoarthritis not responsive to oral pain medication.
Methods/Design: This is a double-blinded, randomized controlled trial. A total of 135 patients (aged > 40 years)
with hip osteoarthritis and persistent pain despite oral analgesics visiting a general practitioner or orthopaedic
surgeon will be included. They will be randomized to a gluteal intramuscular corticosteroid injection or a gluteal
intramuscular placebo (saline) injection. The randomization will be stratified for setting (general practitioner and
outpatient clinics of department of orthopaedics). Treatment effect will be evaluated by questionnaires at 2, 4, 6,
and 12 weeks follow-up and a physical examination at 12 weeks. Primary outcome is severity of hip pain reported
by the patients at 2-week follow-up. Statistical analyses will be based on the intention-to-treat principle.
Discussion: This study will evaluate the effectiveness of an intramuscular corticosteroid injection on pain in
patients with hip osteoarthritis. Patient recruitment has started.
Trial Registration: This trial is registered in the Dutch Trial Registry: number NTR2966.
Background
Recent international guidelines recommend intra-articular
(IA) corticosteroid injections for patients with hip osteoar-
thritis (OA) who have moderate to severe pain and no
satisfactory response to oral analgesic/anti-inflammatory
agents [1]. Of the five randomized controlled trials (RCTs)
on this subject [2-6], four showed clinically significant
positive effects with respect to pain reduction (effect size
up to 1.5 at 1 week follow-up) [2,4-6] and one showed no
clinical benefit of an IA injection [3]. In the RCT that
showed no clinical benefit of an IA injection, patients were
biased towards a negative result having been informed
they would receive priority for surgery if their pain wor-
sened after injection [3].
Because the hip joint is adjacent to important neuro-
vascular structures and cannot be palpated, IA injection
under fluoroscopic or ultrasound guidance is advised.
However, these techniques are not always available,
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any medium, provided the original work is properly cited.especially in a primary care setting. Moreover, apart from
being complex, an IA hip injection can be painful for the
patient and can lead to septic arthritis. An effective but
simpler administration technique would be a welcome
addition to the current methods to treat episodes of
increased pain in hip OA.
A double-blind RCT in patients with subacromial
impingement shoulder pain showed almost equal effective-
ness of ultrasound-guided subacromial corticosteroid
injection compared to gluteal (systemic) injection [7]; this
effect was also reported in an earlier study [8]. In addition,
an equal or even more pronounced pain decrease was
found in patients with concurrent hip OA or chronic low
back pain in an RCT assessing the effectiveness of a local
corticosteroid injection in patients with greater trochan-
teric pain syndrome [9,10]. These results indicate a sys-
temic effect of corticosteroids on pain in OA.
A clinically relevant effect of a systemic corticosteroid
injection, offers a less complex alternative for treatment
of patients with hip OA who are not responsive to oral
pain medication. Since IA hip injection is not standard
care in the Netherlands, we decided to conduct a trial
comparing intramuscular (IM) corticosteroid injection
versus IM placebo injection.
Primary objective
This RCT will assess the effectiveness of an IM gluteal
corticosteroid injection versus an IM gluteal placebo
injection for pain in patients with hip OA who have
moderate to severe pain and no satisfactory response to
oral analgesic/anti-inflammatory agents during 12-weeks
follow-up.
Secondary objectives
The study will assess the effectiveness of an IM gluteal
corticosteroid injection versus an IM gluteal placebo injec-
tion in patients with hip OA with regard to function,
mobility and patients’ perceived improvement. Adverse
reactions will be registered and an explorative subgroup
analysis will be performed stratified for setting (general




This is a double-blinded RCT. The Medical Ethics Com-
mittee of the Erasmus University Medical Center
approved the trial (MEC2011-115). All patients will pro-
vide written informed consent.
Patient selection
Patients with hip OA will be recruited in primary care
(general practices in the Rotterdam area) and via hospital
referrals (orthopaedic outpatient clinics in the Rotterdam
area). Treating physicians are asked to select patients
with hip OA and screen them on the inclusion/exclusion
criteria (Table 1). If a patient has bilateral hip OA, the
most painful hip will be selected as the study hip.
Procedures
Eligible patients will receive written study information
from their treating physician. If they show interest, the
physician will fax their contact data to the research
team. The researcher will contact the patient to answer
additional questions. If the patient is interested/willing
to participate, an appointment at the research centre
will be made to sign an informed consent form and
screen on inclusion/exclusion criteria, including assess-
ment of radiologic hip OA. Pelvic anteroposterior (AP)
X-rays taken within 6 months prior to enrolment are
accepted; otherwise an AP pelvic X-ray will be taken.
Two researchers will independently of each other
assess grading of hip OA according to Kellgren-Lawr-
ence (K&L) [11]. If the patient meets the radiologic cri-
teria for participation (K&L score of ≥ 2), baseline
measurement (questionnaire and physical examination)
follows.
Randomisation
An independent pharmacy assistant will allocate each
patient based on computerized randomization lists to
either receive placebo (saline) injection or triamcinolone
acetate 40 mg injection IM. Randomization is stratified for
setting (general practitioner and outpatient clinics of
department of orthopaedics) and uses random blocks of 2
and 4.
Blinding
To assure blinding with respect to the patient,
researcher and treating physician, the trial medication
will be packed and sealed by the pharmacy of the Eras-
mus MC, Rotterdam. An independent research assistant
(who is not otherwise involved in the study) will prepare
and administer, out of sight of the patient, the injection
in the upper lateral quadrant of the gluteal musculature.
The injection will be administered in the gluteal area
ipsilateral of the study hip.
Intervention
Patients who participate in the trial are randomized to
either an IM triamcinolone acetate 40 mg injection once
or an IM saline injection once.
Patients are allowed to continue their usual pain medi-
cation or physical therapy, but are requested not to start
any new therapies regarding their hip OA during study
follow-up.
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Questionnaires at baseline, 2, 4, 6 and 12 weeks
All outcomes are measured at baseline and at 2, 4, 6 and
12 weeks follow-up. The primary outcome is severity of
hip pain reported by the patient at 2 weeks. This will be
measured with two validated questionnaires: an 11-point
numerical rating scale (NRS) in rest and on walking (0-
10, where 0 equals no pain) [12], and the Western
Ontario and McMaster University Osteoarthritis Index
(WOMAC) pain subscale [13]. The WOMAC pain sub-
scale will be converted to a 0-100 score, where 0 equals
no symptoms. The WOMAC is recommended by the
Osteoarthritis Research Society for use in clinical trials in
patients with hip OA to measure pain and disability [13].
Secondary outcomes include the primary outcomes at 4,
6, and 12 weeks follow-up. Additional secondary outcomes
are the disease-specific WOMAC function and stiffness
subscales [13]. Both the function and stiffness subscale of
the WOMAC will be converted to a 0-100 score. Data on
pain and function will also be obtained with the Hip dis-
ability and Osteoarthritis Outcome Score (HOOS) [14],
which was developed as an extended version of the
WOMAC to evaluate the whole domain of patient-rele-
vant outcome in young and active patients and is validated
in the Dutch language [15].
For patients’ perceived recovery a 7-point Likert scale
will be used (score range 1 = ‘worse than ever’ to 7 =
‘major improvement’) [9,16]. Quality of life will be
measured with the Euroqol (EQ-5D) [17]. Constant and
intermittent pain will be obtained with the questionnaire
Intermittent and Constant Osteoarthritis Pain (ICOAP)
taking into account both pain intensity and impact on
quality of life [18]. Patients’ medical consumption will be
registered and adverse reactions noted [9,16]. For this, a
questionnaire will be used that covers the known local and
systemic adverse reactions to corticosteroids. Data on
daily pain and pain medication use will be obtained with a
diary during the first 2-weeks follow-up.
Another secondary outcome is the difference in per-
centage of responders as defined by the OMERACT-
OARSI (improvement in at least 2 of the 3 following
domains: ≥20% improvement in WOMAC pain, ≥20%
improvement in WOMAC function, or markedly
improved on the patients’ global assessment) [17].
At baseline various patient characteristics (gender, age,
height, weight, race, education, marital status, occupa-
tional situation and co-morbidities) are recorded. Table 2
presents an overview of the parameters measured during
follow-up.
Physical examination at baseline and 12-weeks follow-up
Both hip joints will be examined for presence of groin pain
or peri-trochanteric pain at palpation, range of motion and
pain at/during movement for flexion/extension, abduction,
and for internal/external rotation. Hip rotations will be
examined in sitting position with the hips and knees in
90°. Hip flexion/extension and abduction will be examined
Table 1 Patients’ eligibility criteria
Inclusion criteria:
1. Hip OA* according to clinical ACR** criteria
2. Age > 40 years
3. Symptomatic disease for at least 6 months prior to enrolment
4. Radiographic evidence of OA* (Kellgren-Lawrence score ≥ 2)
5. Persistent pain despite receiving optimal doses of oral pain medication for at least 3 weeks. Pain severity (in rest or on walking) defined as ≥ 3
on an NRS
# (0-10 range, 0 = no pain)
Exclusion criteria:







8. Current use of oral corticosteroids, DMARDs
$ or immunosuppressive medication
9. Allergy to corticosteroids
10. Anticoagulant therapy (coumarins)
11. On the waiting list for total hip replacement surgery
12. IA
## injection into the hip in the previous 6 months
13. Radiologic signs of osteonecrosis
14. Participation in other medical trial
15. Pregnancy or lactating female
* OA Osteoarthritis; **ACR American College of Rheumatology;
# NRS Numerical Rating Scale; $ DMARD disease-modifying antirheumatic drugs;
## IA intra-articular
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degrees of range of motion [19].
To gain insight in knee and lumbar spine co-morbid-
ity both knee joints and lumbar spine will be examined.
Pain at palpation of the medial or lateral joint space of
the knee, hydrops and range of motion of flexion/exten-
sion of the knee will be registered. Pain at palpation of
the spinous processes or sacro-iliac joints and lateroflex-
ion and flexion of the lower spine (fingertip-floor dis-
tance and classic Schober test) will be examined [20].
Laboratory assessment
At baseline, two blood samples (9 ml) will be collected.
One to measure the erythocyte sedimentation rate, which
is used for the American College of Rheumatology criteria
of hip OA [21]. The other for high-sensitive C-reactive
protein (hs-CRP) to gain insight in the inflammatory pro-
cesses. The samples will be analysed at the Trial Labora-
tory Department of the Erasmus MC.
Sample size
Data from the Qvistgaard et al. study (patients with hip
OA from primary care and secondary care) were used to
calculate our sample size [6]. That study showed a base-
line standard deviation (SD) of 20 for pain at rest and at
walking (0-100 visual analogue scale; VAS). Assuming a
minimal clinically relevant difference of 10 points (effect
size 0.5), 64 patients per group will be needed to show a
statistically significantly difference using 80% power and
with a 5% alpha.
In that same study [6] the WOMAC total score (0-96)
was used with an SD of 15. Standardized to a 0-100 score
this SD is almost 16. Assuming an SD of 16 and an 8-
point difference as clinically relevant (effect size 0.5), the
same sample size is needed.
We checked these scores in a Dutch study population
with hip OA, i.e. those with a K-L score of the hip ≥ 2
and a VAS pain score ≥ 30, participating in the GOAL
study [22]. This showed they had a mean VAS score of
56.4 with an SD of 19.3, a mean WOMAC pain score of
51.2 with a SD of 16.4; these data are very similar to the
SDs in the study of Qvistgaard et al. Therefore, in the
planned trial, we will include 135 patients, anticipating
only 5% loss to follow-up based on the relatively short
follow-up and earlier experience with loss to follow-up
[22,23].
Data analyses
Data analysis will be performed based on the ‘intention
to treat’ principle.
Descriptive statistics will be used to describe patient’s
characteristics, items of physical examination, and the
severity of radiologic hip OA.
Table 2 Timing of measurements and outline of primary and secondary outcome measures
Baseline Daily diary for 2 weeks 2 weeks 4 weeks 6 weeks 12 weeks
Primary outcome measures
Pain score (WOMAC*) x x x x x
Pain Score (NRS**) x x x x x x
Secondary outcome measures
Function score (WOMAC) x x x x x
Stiffness score (WOMAC) x x x x x
HOOS*** x x x x x
Quality of life (EuroQol EQ-5D) x x x x x
Constant and intermittent pain (ICOAP
#) x xxxx
Use of medication x x x x x x
Medical consumption x x x x x
Adverse reactions x x x x








* WOMAC Western Ontario and McMaster University Osteoarthritis Index
** NRS Numerical Rating Score
*** HOOS Hip disability and Osteoarthritis Outcome Score
# ICOAP Intermittent and Constant Osteoarthritis Pain
## ESR Erythrocyte Sedimentation Rate
### Hs-CRP high sensitive C-reactive protein
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to analyze the continuous outcome measures. Fixed effects
will be time, time by therapy and the covariates we adjust
for. For patients lost to follow-up, we will include all
observed data in the analysis. Adjustment will be made for
those baseline variables that change the effect estimate by
more than 10%. Similar analyses with Generalized Estimat-
ing Equations techniques for repeated measures will be
done for dichotomous outcome measures.
Subgroup analyses for setting will be analyzed by
assessing interaction effects between type of intervention
and setting on the primary outcomes; in addition, the
estimates will be shown for both settings separately. We
realize that these subgroup analyses will remain solely
explorative because our sample size is not directed to
powerful subgroup analyses.
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